Shenyang Haisike Pharmaceutical

Shenyang Haisike Pharmaceutical is a prominent subsidiary of the Haisike Pharmaceutical Group, serving as a core hub for the research, development, and large-scale manufacturing of innovative small molecule drugs. The company specializes in high-growth therapeutic areas including anesthesiology, analgesia, parenteral nutrition, and metabolic diseases. Its flagship product, Ciprofol (HSK3486), is a novel intravenous anesthetic that has successfully challenged established standards in the Chinese market and is undergoing global clinical development. Shenyang Haisike operates advanced manufacturing facilities that adhere to international GMP standards, supporting a robust pipeline of proprietary candidates. The company is a key driver in the parent group's transition from a generic pharmaceutical manufacturer to an innovation-led biopharmaceutical enterprise.